Articles On IDT Australia (ASX:IDT)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Pfizer has won a spirited bidding war for the GLP-1 drug developer Metsera Pharmx launches its eBay for chemists Gough-era biotech stocks maintain the rage     A fierce US$10 billion bidding war for the Nasdaq-listed anti-obesity drug mak...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

ASX overcomes tepid morning to rise 36 points or 0.41pc Strong gains in blue chips, banks, real estate Heavy sell down in resource stocks as gold retreats from all-time highs Market stages blue chip recovery The ASX wasn’t quite sure whic...

While sector conditions are improving, investors still can pick up marked-down, revenue-generating biotechs Dozens of offshore life science plays trade at below net asset backing, but the discounts on the ASX aren’t quite so harsh Investor...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Australia’s S&P/ASX 200 rose 3.10% in August and has posted gains of 12.33% so far for CY25 Materials led the gainers up 9.19%, while Healthcare fell 13.21% with CSL having its biggest ever daily fall Rare earths explorer Kaili Resourc...

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

ASX surges 1.23pc on broad strength 11 of 11 sectors positive throughout trade ASX just 0.07pc off all-time high Market powers higher with all cylinders firing The ASX moved to its own tune today, making strong gains in the first hour an...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Veteran drug contract manufacturer IDT Australia (ASX:IDT) can thank Donald Trump and Robert F Kennedy Junior’s shambolic approach to reforming US healthcare that shuns usual scientific rigour and has crimped medical research funding. Why?...

Oil hits four-year low, returning to early 2021 levels Energy sector leads ASX down 1.8% China intervenes in home markets as US trade war escalates   The funeral march continues for the global economy, as the tariff stoush and trade war c...

Healthcare and medical manufacturing in Australia is gaining momentum supported by initiatives from federal and state governments CSL, IDT Australia, Optiscan and Trajan Group among healthcare companies with manufacturing facilities in Mel...

PolyNovo Ltd (ASX: PNV) shares are sinking on Tuesday morning. At the time of writing, the ASX 200 healthcare share is down 9% to a 52-week low of $1.14. What is PolyNovo? PolyNovo is a medical technology company based in Melbourne that spe...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

The ASX200 closed down 0.75% at 8,193 points. Analyst consensus is now that Trump will introduce the tariffs he’s forewarned, and local markets have priced it in. Aussie 3Y government bond yields suggest the RBA now won’t cut until Se...

IDT Australia (ASX:IDT) has confirmed its proposed takeover offer from a company called Myndbio for 15cps has been scrapped. While that deal was higher than IDT’s 11.5cps closing price on Tuesday, IDT says that somewhere along the way d...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Neuren shows promise in Angelman drug but shares down 7pc Avita aims for profitability by Q3 FY25 IDT lands $2.5-$4m mRNA contract with Sanofi   Neuren’s Angelman drug shows promise Market darling Neuren Pharmaceuticals (ASX:NEU) has just...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

HITIQ has secured a pivotal US patent for its Nexus technology BlinkLab has joined forces with Mental Care Group in Europe to enhance ADHD diagnosis IDT Australia has reported a strong finish to the fiscal year   HITIQ gets US patent HITI...

Pharmaceutical manufacturer and medicinal cannabis group IDT Australia (ASX: IDT) has sweetened the pot for potential international suitor Myndbio after reporting a 92 per cent lift in revenue for FY24. IDT, which revealed last month it re...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

FDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s benefits outweigh risks, call for further research. South Africa legalises personal cannabis use, setting precedent for African nations    G...

Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal   Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&amp...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Pharmaceutical manufacturing company IDT Australia (ASX: IDT) has been awarded a grant by the Victoria state government to partly fund the establishment of Australia’s first current good manufacturing practice antibody-drug-conjugate (ADC)...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

Australian shares declined sharply following stronger-than-expected US retail sales data, dampening hopes for interest rate cuts and triggering a 1.26 per cent drop to the S&P/ASX 200, marking the third consecutive session of losses. Th...

  Paul McDonald – CEO – IDT Australia (ASX:IDT) is an expert partner in the production and manufacture of pharmaceutical products, including medicinal cannabis.

Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month   It hasn’t been a stellar month for global cannabis stocks, with the index falling by...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

By Tim Boreham, Editor, The New Criterion Profit season brings out the best and worst in small caps – and sometimes both at once While inconsistent, the just-concluded profit reporting season has provided succour to investors in the small-c...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients  How ASX weed stocks have performed over the past week and month   Scientists in Brazil said they’ve d...